Compare CECO & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | SRPT |
|---|---|---|
| Founded | 1966 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2002 | 2000 |
| Metric | CECO | SRPT |
|---|---|---|
| Price | $78.91 | $18.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 28 |
| Target Price | ★ $67.67 | $25.76 |
| AVG Volume (30 Days) | 273.5K | ★ 2.3M |
| Earning Date | 01-01-0001 | 04-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 140.34 |
| EPS | ★ 1.29 | N/A |
| Revenue | N/A | ★ $1,901,979,000.00 |
| Revenue This Year | $39.58 | $14.67 |
| Revenue Next Year | $14.60 | N/A |
| P/E Ratio | $61.07 | ★ N/A |
| Revenue Growth | N/A | ★ 52.97 |
| 52 Week Low | $17.57 | $10.42 |
| 52 Week High | $81.72 | $109.55 |
| Indicator | CECO | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 67.07 | 43.14 |
| Support Level | $72.04 | $17.45 |
| Resistance Level | $81.72 | $18.70 |
| Average True Range (ATR) | 3.67 | 1.00 |
| MACD | 0.29 | -0.01 |
| Stochastic Oscillator | 72.28 | 37.11 |
CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.